


A Mark of Recognition



Two years ago, Smith Kline and French Research Institute received the Queen's Award for Technological Achievement resulting from H₂ receptor antagonist research and the development of cimetidine.


Since it became generally available over three years ago, 'Tagamet', by its unique action in reducing gastric acid, has revolutionised the treatment of disorders such as duodenal ulcer, benign

gastric ulcer and reflux oesophagitis, where acid plays a part.

For many patients it has brought a new standard of pain relief and healing. In the United Kingdom alone 'Tagamet' has been prescribed for an estimated one million patients.

Tagamet

cimetidine



PRESCRIBING INFORMATION

Presentations

Tagamet Tablets: P10002/0063 each containing 200 mg cimetidine. 100 (13.2) 200 (264)

Tagamet Syrup: P10002/0073 containing 200 mg cimetidine per 5 ml syrup. 200 ml (4.29)

Indications

Duodenal ulcer benign gastric ulcer reflux oesophagitis

Dosage

Duodenal ulcer: Adults: 200 mg tds with meals and 400 mg at bedtime. 10 g/day for at least 4 weeks for full instructions see Data Sheet. To prevent relapse: 400 mg at bedtime or 400 mg morning and evening for at least 6 months.
Benign gastric ulcer: Adults: 200 mg tds with meals and 400 mg at bedtime. 10 g/day for at least 6 weeks for full instructions see Data Sheet.
Reflux oesophagitis: Adults: 400 mg tds with meals and 400 mg at bedtime. 10 g/day for 4-6 weeks.

Cautions

Impaired renal function: reduce dosage (see Data Sheet). Potential of oral anticoagulants: see Data Sheet. Prolonged treatment: observe patients periodically. Malignant gastric ulcer: may respond symptomatically. Avoid during pregnancy and lactation.

Adverse reactions

Drowsiness, dizziness, rash, tiredness. Rarely, mild, dysrhythmias, reversible liver damage, confusion, ataxia, usually in the elderly or very ill. Interstitial nephritis.

Full prescribing information is available from:

SK&F
a SmithKline company

SmithKline & French Laboratories Limited
Ware, Hertfordshire AL9 1JY
Telephone: Welwyn Garden 25111
Tagamet is a trademark
© SmithKline & French Laboratories Limited 1980

CONCLUSIVE EVIDENCE IN CROHN'S TREATMENT



The use of Salazopyrin in Ulcerative colitis is well established, and for a number of years more positive links for its use in treating active Crohn's disease have emerged.

Recently in the U.S.A. a National Cooperative Crohn's Disease Study (NCCDS) looked at 569 patients from 14 Centres over a period of approximately 5 years. Prednisone, azathioprine and sulphasalazine (Salazopyrin) were selected as the agents most meriting clinical trial.

All three were studied for both suppressive and prophylactic efficacy and toxicity.^{1,2} In terms of efficacy! the results of the drug trials showed that "sulphasalazine was significantly superior to placebo in the treatment of active Crohn's disease." Sulphasalazine proved significantly superior in "patients with colon involvement, whether or not the small bowel was involved."

Patients with recent onset of disease who had not received any treatment prior to the study "... did not respond well to any of the drugs except sulphasalazine..."

Adverse reactions and relative toxicity of the three drugs were also mentioned and evaluated.²

"Sulphasalazine was the least toxic of the three drugs used..." while "prednisone and azathioprine showed an approximately equal incidence of toxic reactions."

On balance it was concluded that:-
"Sulphasalazine proved to be the safest effective suppressive drug for Crohn's disease."

Proven efficacy and acceptability in Crohn's Disease

SALAZOPYRIN
sulphasalazine

Prescribing Information

Dosage and Administration

Plain or EN Tablets: In acute moderate attacks 2-4 tablets 4 times a day. In severe attacks steroids should also be given. After 2-3 weeks the dose may gradually be reduced to the maintenance level of 3-4 tablets daily which should be given indefinitely.

Suppositories: Two inserted morning and night the dosage being gradually reduced after 3 weeks as improvement occurs.

Enema: One enema should be given daily preferably at bed time. This preparation contains an adult dose of Salazopyrin. Patient instructions are enclosed in each box.

Children: Reduce the adult dose on the basis of body weight.

Contra-indications.

Warnings etc

Contra-indications: Contra-indicated in sensitivity to salicylates and sulphamides. Infants under 2 years.

Enema only: Sensitivity to parabens.

Adverse Reactions: Side-effects common to salicylates or sulphamides may occur. Mild and usually transient reactions: loss of appetite and raised temperature which may be relieved on reduction of dosage.

If serious reactions occur the drug should be discontinued. Rarely the following adverse reactions have been reported:

Haematological: e.g. Hemolytic anaemia, haemolytic anaemia, leucopenia, agranulocytosis and aplastic anaemia.

Hypersensitivity: e.g. Rash, fever.

Gastrointestinal: e.g. Impaired folate uptake, stomatitis.

CNS: e.g. Headache, peripheral neuropathy.

Renal: e.g. Proteinuria, crystalluria. Also: Stevens Johnson syndrome and lung complications e.g. Fibrosing alveolitis.

Precautions: Care in cases of porphyria, allergic renal or hepatic disease, glucose 6 PD deficiency. Blood checks should be made initially and periodically.

Pregnancy: The benefit to risk ratio must be carefully evaluated when the drug is given during pregnancy.

Packages & Prices:
Plain Tablets 100 & 500
£5.05 for 100 tablets
EN Tablets 100 & 500
£6.55 for 100 tablets

Suppositories 10 & 50
£2.05 for 10 suppositories
Enemas 7 £9.80 for 7 enemas.

Product Licence Numbers:
Plain Tablets 0009/500b
EN Tablets 0009/5007
Suppositories 0009/5008
Enema 0009/0023

References:
1 Gastroenterology (1979) 77, 847-849.
2 Gastroenterology (1979) 77, 870-882.



Pharmacia
Salazopyrin (regd.) sulphasalazine is a product of Pharmacia (Great Britain) Ltd, Prince Regent Road, Hounslow, Middlesex TW3 1NF.
Tel: 01-572 7321.
Further information is available on request from the Company.



Ease the spasm. Ease the mind.

LIBRAXIN

clidinium bromide and chlordiazepoxide

Clidinium bromide to calm the gut. Chlordiazepoxide to calm the mind.

Indications For the control of hypersecretion, hypermotility and emotional factors associated with gastro-intestinal disorders, such as nervous dyspepsia, peptic ulcer, cardiospasm, pylorospasm, nervous or irritable colon.

Dosage 1 or 2 tablets three or four times daily. In elderly patients, it is recommended that the initial dose be 1 tablet twice daily.

Contra-indications Because of its anticholinergic effects, Librax should not be given to patients suffering from glaucoma or prostatic enlargement.

Precautions Patients should avoid alcohol while under treatment with Librax, since the individual

ROCHE

response cannot be foreseen. Patients' reactions (driving ability, operation of machinery, etc.) may be modified to a varying extent, depending on dosage and individual susceptibility. The established medical principle of prescribing medicaments in early pregnancy only when absolutely indicated should be observed.

Side-effects Side-effects are infrequent and are controlled by reduction of dosage. They include

drowsiness, muscle weakness, dryness of the mouth, blurring of vision, constipation and hesitancy of micturition.

Presentation Libraxin tablets containing 5mg chlordiazepoxide and 2.5mg clidinium bromide in packings of 100 and 500.

Basic NHS Cost 1 tablet 3 times daily 7.4p/day ex 500 pack.

Licence Number 0031/5024

Licence Holder Roche Products Limited, PO Box 8 Welwyn Garden City, Hertfordshire AL7 3AY
Libraxin is a trade mark

Carbenoxolone can heal gastric and duodenal ulcer

“Carbenoxolone...acts, in healing these ulcers, by restoring the gastric physiology to normal – rather than by creating a non-physiological artifice, such as that produced by antacids and H₂-receptor antagonists...”¹

2 IMPORTANT ACTIONS

1. EXTENDS LIFE-SPAN OF EPITHELIAL CELLS²

2. INCREASES MUCUS PRODUCTION³

2 IMPORTANT PRODUCTS

BIOGASTRONE
carbenoxolone
tablets for gastric ulcer

DUOGASTRONE
carbenoxolone
positioned-release capsules for duodenal ulcer

1. In "Peptic Ulcer Healing. Recent Studies on Carbenoxolone." 1978. Lancaster, MTP Press Ltd., p.1. 2. *ibid.*, pp. 9-20.
3. In 4th Symposium on Carbenoxolone. 1975. London, Butterworths, p. 161.

Biogastrone and Duogastrone are registered trade marks.

Made under licence from Biorex Laboratories. Brit. Pat. Nos. 843133 and 1093286.
Further information available from Winthrop Laboratories, Surbiton-upon-Thames, Surrey.

AMERICA'S MOST PRESTIGIOUS GASTROENTEROLOGY JOURNAL –

GASTROENTEROLOGY

OFFICIAL PUBLICATION OF THE
AMERICAN GASTROENTEROLOGICAL ASSOCIATION

Internationally recognized as America's most prestigious gastroenterological journal, GASTROENTEROLOGY deals with all aspects of the digestive tract and liver. Original papers include clinical and basic science articles, as well as cogent reports of investigative findings and clinical case studies.

EDITOR**John S. Fordtran**

Department of Internal Medicine, Baylor University Medical Center, 3500 Gaston Ave., Dallas, Texas 75246

EDITOR OF LIVER SECTION

Burton Combes, University of Texas, Southwestern Medical School, 5323 Harry Hines Boulevard, Dallas, Texas 75235

ASSOCIATE EDITORS

Raj K. Goyal, San Antonio, Texas, John H. Walsh, Los Angeles, California, Athol Ware, Dallas, Texas, Jon I. Isenberg, (Selected Summaries Editor), Los Angeles, California, Armand Littman, (Book Review Editor), Hines, Illinois, Marvin M. Schuster, (Audiovisual Editor), Baltimore Maryland

CHAIRPERSON OF EDITORIAL BOARD

Fred Kern, Jr., Denver, Colorado

EDITORIAL BOARD

James L. Boyer, Chicago, Illinois, Harold O. Conn, West Haven, Connecticut, Allan R. Cooke, Iowa City, Iowa, Edwin Englert, Jr., Salt Lake City, Utah, Michael Field, Chicago, Illinois, Harvey Goldman, Boston, Massachusetts, Alan F. Hofmann, San Diego, California, Bernard M. Jaffe, St. Louis, Missouri, Ronald M. Katon, Portland, Oregon, Young S. Kim, San Francisco, California, Raymond S. Koff, Boston, Massachusetts, Summer C. Kraft, Chicago, Illinois, Gabriel M. Makhlof, Richmond, Virginia, Charles E. Pope II, Seattle, Washington, Allan G. Redeker, Downey, California, Malcolm M. Stanley, Chicago, Illinois, Jerry S. Trier, Boston, Massachusetts, Elliot Weser, San Antonio, Texas, Jack Wittenberg, Boston, Massachusetts

RECENTLY PUBLISHED ARTICLES:

Percutaneous Transhepatic Portography in the Assessment of Portal Hypertension. Clinical Correlations and Comparison of Radiographic Techniques. G. Smith-Laing, M.E. Camilo, R. Dick and S. Sherlock, Departments of Medicine and Radiology, Royal Free Hospital, London, England.

Liver Structure and Function in Patients Poisoned with Chlordecone (Kepone). P.S. Guzelian, C. Vranian, J.J. Boylan,

W.J. Cohn and R.V. Blanke, Liver Study Unit, Departments of Medicine and Pathology, Medical College of Virginia, Richmond, Virginia

Cholesterol Absorption During Bile Acid Feeding. Effect of Ursodeoxycholic Acid (UDCA) Administration. M. Ponz de Leon, N. Carulli, P. Loria, R. Iori and F. Zironi, Istituto di Clinica Medica Generale e Terapia Medica, Universita di Modena. Modena, Italy

Chronic Diarrhea of Unknown Origin. N. W. Read, G. J. Krejs, M.C. Read, C.A. Santa Ana, S.G. Morawski and J.S. Fordtran, Departments of Internal Medicine, Southwestern Medical School and Baylor University Medical Center, Dallas, Texas

Zinc Deficiency: A Complication of Crohn's Disease. C. McClain, C. Soutor and L. Zieve, Departments of Medicine and Dermatology, University of Minnesota, Minneapolis Veterans Administration Medical Center and Hennepin County Hospital, Minneapolis, Minnesota

Hemochromatosis: 1980 Update. L.W. Powell, M.L. Bassett and J.W. Halliday, Department of Medicine, University of Queensland, Royal Brisbane Hospital, Brisbane, Australia

Acetaminophen Hepatotoxicity. M. Black, Department of Medicine, Liver Unit, Temple University School of Medicine, Philadelphia, Pennsylvania

Sample copies available upon request from Journals Fulfillment Department, Elsevier North Holland, Inc.

SUBSCRIPTION INFORMATION:

1980: Volumes 78 and 79 (2 volumes in 12 issues) 1980:

Individuals: \$48.00

Institutions: \$75.00

Interns and Residents: \$36.00

Note: All individual subscriptions must be prepaid. Subscribers outside the United States should add \$9.00 for surface mail; \$20.00 for air mail to Europe and Canada; and \$45.00 for air mail to the rest of the world.




ELSEVIER North Holland, Inc.

52 Vanderbilt Avenue New York, NY 10017

The Pancreatic challenge!

RIA-gnost[®] Trypsin



Simple and fast double antibody radioimmunoassay

Specific for Trypsin and Trypsinogen, unaffected by Trypsin inhibitors

More specific than total α -amylase for the diagnosis of acute and chronic pancreatitis, carcinoma of the pancreas and cystic fibrosis

The first radioimmunoassay for the determination of Trypsin concentration in serum, plasma, urine and pancreatic juice.

Hoechst Aktiengesellschaft
Verkauf Pharma
ZPM/Diagnostics
D-6230 Frankfurt (Main) 80
W-Germany

Hoechst



Manufactured by Behringwerke AG Marburg/Lahn, associated with Hoechst AG

Unique Ulcerative




Colifoam is a unique therapy for ulcerative colitis, being a topical anti-inflammatory with exceptional benefits over the rectal enema in terms of simplicity and convenience.

Gamma photography studies^{1,2} have shown that a single dose of Colifoam remains in contact with the rectal mucosa for several hours. In one of these studies¹ the foam was seen to reach the sigmoid colon in most patients. The second study,² using a different protocol which included healthy subjects, did not confirm this finding but the authors concluded:

“Unquestionably, however, the foam is more comfortable and easier to retain

Colitis




than a retention enema, and since the patient need not be immobilised, the foam obviously has a place in outpatient practice for patients with proctitis and distal ulcerative colitis."

Colifoam: hydrocortisone acetate foam supplied in a metered dose dispenser, delivering approximately 5 ml. of Colifoam rectal foam containing 10% hydrocortisone acetate.

Colifoam

hydrocortisone acetate foam

comfort and convenience
in ulcerative colitis



References

1. *British Medical Journal* (1979) 2:822.
2. *ibid.* (1979) 1:1751.

Presentation

White, odourless aerosol foam containing hydrocortisone acetate 10%, with inert propellants.

Uses

Anti-inflammatory corticosteroid therapy for the topical treatment of ulcerative colitis, proctosigmoiditis and granular proctitis.

Dosage and Administration

One applicatorful inserted into the rectum once or twice daily for two or three weeks and every second day thereafter. Shake can vigorously before use (illustrated instructions are enclosed in each pack). One applicatorful of Colifoam provides a dose of approximately 90-110mg of hydrocortisone, similar to that used in a retention enema for the treatment of ulcerative colitis, sigmoiditis and proctitis. Satisfactory response usually occurs within five to seven days.

Contra-indications and Warnings etc.

Local contra-indications to the use of intrarectal steroids include obstruction, abscess, perforation, peritonitis, fresh intestinal anastomoses and extensive fistulas. General precautions common to all corticosteroid therapy should be observed during treatment with Colifoam. Treatment should be administered with caution in patients with severe ulcerative diseases because of their predisposition to perforation of the bowel wall. Safety during pregnancy has not been fully established.

Pharmaceutical Precautions

Do not refrigerate, incinerate or puncture the aerosol can. Shake vigorously before use. Keep out of reach of children.

Package Quantities

Aerosol canister containing 20g (14 applications) plus a plastic applicator and illustrated leaflet.

Basic NHS Cost

£6.90.

Product Licence No.

0036/0021

Further information is available on request from:

Stafford-Miller Limited,
Professional Relations Division, Hatfield,
Herts. AL10 0NZ.



In dyspepsia, antacids
only cloud the issue.

Maxolon
metoclopramide
clears it.



Maxolon protects the gastric mucosa from over-long exposure to gastric acid¹ by promoting normal peristalsis and gastric emptying.^{2,3} This action contrasts with that of antacids.

By restoring the stomach's normal control, symptoms described by the patient as fullness, pain, heartburn and discomfort can be effectively treated and their recurrence prevented⁴.

To the patient, Maxolon is the simple and convenient therapy to replace his repetitive antacid prescriptions.

Prescribing Information

Indications

Dyspepsia, heartburn and flatulence associated with the following conditions e.g., Reflux oesophagitis, Gastritis, Hiatus hernia, Peptic ulcer.

Adult Dosage (oral)

Adults 10mg

1 tablet or 10ml syrup 3 times a day.

Young adults (15-20 years) 5-10mg

½ tablet or 5-10ml syrup 3 times a day commencing at the lower dosage.

Note: Total daily dosage of Maxolon, especially for children and young adults should not normally exceed 0.5mg/kg body-weight.

Side-effects and Precautions

There are no absolute contra-indications to the use of Maxolon.

Various extra-pyramidal reactions to Maxolon, usually of the dystonic type, have been reported. The incidence of these reactions in children and young adults may be increased if daily dosages higher than 0.5mg/kg body-weight are administered.

The majority of reactions occur within 36 hours of starting treatment and the effects usually disappear within 24 hours of withdrawal of the drug. Should treatment of a reaction be required, an anticholinergic anti-Parkinsonian drug e.g. benapryzine, or a benzodiazepine may be used. Since extra-pyramidal symptoms may occur with both

Maxolon and phenothiazines, care should be exercised in the event of both drugs being prescribed concurrently.

Raised serum prolactin levels have been observed during metoclopramide therapy; this effect is similar to that noted with many other compounds.

Maxolon's action on the gastro-intestinal tract is antagonised by anticholinergics. Although animal tests in several mammalian species have shown no teratogenic effects, treatment with Maxolon is not advised during the first trimester of pregnancy.

Following operations such as pyloroplasty or gut anastomosis Maxolon therapy should be withheld for three or four days as

vigorous muscular contractions may not help healing.

Availability and NHS Prices

Tablets 10mg (£5.84 per 100).
Syrup 5mg/5ml (£2.42 for 200ml).

A paediatric liquid presentation and ampoules for injection are also available.

Average daily cost of Maxolon tablets (ex. 500 pack) 17p. Prices correct at January 1979. Further information is available on request to the company.

Maxolon (metoclopramide) is a product of Beecham Research Laboratories, Brentford, England. A branch of Beecham Group Limited. Maxolon, BRL and the Company logo are registered trade marks.

Indications

Intravenous sedative cover before and during unpleasant surgical and medical procedures.

Dosage

0.2 mg/kg body weight. The usual adult dose is 10-20 mg but more may be needed on occasions. In elderly patients half the usual adult dose.

Administration

With the patient in the supine position the injection should be given slowly (0.5 ml Valium Roche ampoule solution per half minute) into a large vein at the antecubital fossa until the patient becomes drowsy, his speech becomes slurred and there is ptosis. He should still be able to respond to requests. Provided these conditions for administration are adhered to the risk of possibility of hypotension or apnoea occurring will be greatly diminished. A second person should be present and resuscitation facilities should be available.

Precautions and side-effects

Patients should not be allowed to leave the surgery until one hour at least has elapsed from the time of injection and should always be accompanied by a responsible adult with a warning not to drive or operate machinery for the rest of the day and to avoid alcohol. In patients with organic cerebral changes or with cardiorespiratory insufficiency, injections of Valium Roche

should not be employed unless, in an emergency or in hospital, indicated and then should be given slowly and in reduced dosage.

The possibility of intensified sedative effects and severe respiratory and cardiovascular depression should be considered if central depressant drugs are given, particularly by parenteral route, in conjunction with Valium Roche for Injection. Valium Roche

should not be given in early pregnancy unless absolutely indicated. Intravenous injection may be associated with local reactions including thrombophlebitis.

Presentation

Ampoules containing 10 mg diazepam in 2 ml and 20 mg in 4 ml in packings of 10.

Product Licence Numbers

0031/0068 (ampoules 10 mg)
0031/5128 (ampoules 20 mg)

Basic NHS Cost

Ampoules 10 mg x 10 £2.22
20 mg x 10 £3.28

References

- 1 Brit med J 1976 2:20
- 2 Brit J Hosp Med 1976 16:7
- 3 Scand J Gastroent 1979 14:747
- 4 Scand J Gastroent 1978 13:333
- 5 Gut 1976 17:655
- 6 Brit J Hosp Med 1971 6(Suppl):52
- 7 Amer J Gastroent 1976 66:523
- 8 Amer J med Sci 1974 267:151
- 9 Gut 1976 17:975
- 10 Advanced Medicine 1978 No 14 p19

Intravenous Valium Roche



the preferred sedative
for gastro-intestinal
endoscopy

Vast would be an apt description of the experience with intravenous Valium Roche in gastro-intestinal endoscopy – an experience which covers the range of procedures and patients of all age groups.* Endoscopy without premedication is for many patients an unpleasant experience.† Intravenous Valium Roche sedation improves patient acceptance without impairing their ability to co-operate. Keeping medication to a minimum is particularly important for out-patients‡ and avoidance of analgesics leads to faster recovery times.§ In certain circumstances where prolonged intubation is required or pain from an operative procedure likely, the addition of a narcotic analgesic such as pethidine may be desirable.¶ Neuroleptanalgesia has also been used to good effect with intravenous Valium Roche.‡ The amnesic effect of intravenous Valium Roche undoubtedly contributes to the excellent acceptance by patients and their willingness to undergo repeat procedures.¶ The shortness of the amnesic effect is a boon for the operator too when treating out-patients.

Age is no barrier to intravenous Valium Roche sedation for gastro-intestinal endoscopy.* Whether the patient is six weeks or 103-years-old favourable results have been obtained.‡ This is true also for many poor-risk patients including those with liver disease in whom intravenous Valium Roche has been extensively used.‡-10 The dosage must, of course, be adjusted to the patient's needs and the necessary precautions observed.

*Annotated bibliography of references available on request.

Intravenous Valium Roche

diazepam

where experience
counts



Roche Products Limited
PO Box 8, Welwyn Garden City,
Hertfordshire AL7 3AY

Valium is a trade mark
0954183/3B0



NEW OP-SITE SKIN CLOSURE. AN OUTSTANDINGLY SIMPLE, NON-INVASIVE TECHNIQUE.

Op-Site Skin Closures represent a major new advance in surgical wound closure and have been designed to produce significant advantages over existing methods.

Being a sutureless technique, they produce no localised tension or ischaemia at the wound edge. They eliminate foreign body reactions and the risk of infection at the puncture site.

Produced from a transparent, adhesive, polyurethane membrane, Op-Site Skin Closures are easy to apply, strong and conform readily to body contours. The fenestrations along their length allow for correct appositioning of the wound.


Op-Site Skin Closures are comfortable and can stay in place for up to 14 days. This, together with the non-invasive technique

employed, greatly enhances the final cosmetic effect.

Removal is painless - relieving patients, particularly children, of the anxiety normally associated with suture removal.

In clinical trials, 94 out of 100 patients were satisfactorily treated⁽¹⁾. They were infection free and enjoyed a superior cosmetic effect.

Contact Smith & Nephew Medical now for more details.



**Smith & Nephew
Medical**

WELWYN GARDEN CITY, HERTFORDSHIRE
TELEPHONE (07073) 25151

1.5 Westaby BSc, MB, BS, FRCS. Evaluation of a new product for Sutureless Skin Closure (March 1980). Annals of the Royal College of Surgeons.

New for Urostomy!


a new standard of comfort and security

SURGICARE System 2

Trademark

Stomahesive™ Flange
the best in skin care

Urostomy pouches simply snap onto the Stomahesive™ Flange



Surgicare™ System 2 saves the patient from the trauma of peeling off adhesive bags. The Stomahesive™ Flange can be left on the skin undisturbed for several days whilst the pouches are replaced as often as necessary. It makes possible a leak-free attachment of appliances to the skin thereby providing a unique degree of comfort free of irritation and soreness often associated with ordinary adhesives. Surgicare™ System 2 takes full advantage of these benefits which are particularly evident in the management of urostomies.

● The non-return valve permits easy access of urine to the lower part of the pouch and efficiently prevents the return of urine to pool in the area of the stoma thus the Stomahesive™ wafer is protected from the breakdown effects of urine and remains secure and leak-free for several days.

Squibb Surgicare Limited
Regal House
Twickenham TW1 3QT
Telephone 01-892 0164
Made in England
Authorised user
of the trademarks

Please send me your illustrated brochure on Surgicare™ System 2 Urostomy management
Address your envelope to Squibb Surgicare Limited, Freepost TK 245, Twickenham TW1 1BR

Name BLOCK CAPITALS

Address

No stamp required



“... the major cause of sepsis after surgery of
the gastrointestinal tract
or female genital
tract”.

Br.Med.J. 1, 318, 1976

METRONIDAZOLE
INJECTION

**proves decisive
in anaerobic
infections**

Only with recent
improvements in bacterial culturing
techniques has the pathogenic role of anaerobes
in post-surgical infections been fully recognized.¹⁻³
Now 'Flagyl' Injection offers you a decisive means of treating
these infections—which are often life-threatening and often resistant
to established antimicrobials. The response to 'Flagyl' Injection is rapid and
dependable,² as it is consistently bactericidal to pathogenic anaerobes at tissue
concentrations easily achieved in treatment. Bacterial resistance is not a problem,^{2,4}
and 'Flagyl' is highly acceptable—as eighteen years of use in other indications has established.

Dosage: Treatment: adults and children over 12 years: 100 ml by intravenous infusion eight-hourly, administered 5 ml per minute. Oral medication with 400 mg three times daily should be substituted as soon as this becomes feasible. Treatment for seven days should be satisfactory in most cases. Children under 12 years: as for adults but the single intravenous dose is based on 1.5 ml (7.5 mg metronidazole) per kg bodyweight and the oral dose on 7.5 mg per kg bodyweight. Prevention: adults and children over 12 years: 100 ml by intravenous infusion immediately before, during or after operation, followed by the same dose eight-hourly until oral medication (200 to 400 mg three times daily) can be given to complete a seven-day course. Children under 12 years: as for adults but the single intravenous dose is based on 1.5 ml (7.5 mg metronidazole) per kg bodyweight and the oral dose on 3.7 to 7.5 mg per kg bodyweight. Precautions: pregnancy; lactation; clinical and biological surveillance if recommended duration of treatment exceeded; dosage may be halved for patients with renal failure; avoid alcohol; if 'Flagyl' is to be given to patients receiving oral anticoagulants the dosages of the latter should be recalibrated. Side effects and adverse reactions: occasionally an unpleasant taste, furred tongue, nausea, vomiting (very rarely), gastro-intestinal disturbance. Drowsiness, dizziness, headache, ataxia, skin rashes, pruritus, inco-ordination of movement, darkening of the urine very rarely. During intensive and/or prolonged therapy, peripheral neuropathy has been reported. A moderate leucopenia has been reported but the white cell count has always returned to normal before or after treatment has been completed. Transient epileptiform

seizures in a few patients undergoing intensive, high-dosage metronidazole radiosensitization therapy.

'Flagyl' metronidazole
Tablets 200 mg PL 0012/5256
400 mg PL 0012/0084
Suppositories 500 mg PL 0012/0113
1 gram PL 0012/0114
Injection 0.5% w/v PL 0012/0107

Basic NHS (as at May 1979)

Injection for i.v. infusion Bottle of 100 ml £6.40.

References 1. Willis, A.T. (1977) Scottish Medical Journal, 22, 155. 2. Willis, A.T. et al. (1977) British Medical Journal, i, 607. 3. Finegold, S.M. Anaerobic Bacteria in Human Disease, Academic Press Inc. New York, 1977. 4. Willis, A.T. et al. (1975) Journal of Antimicrobial Chemotherapy, 1, 393, 1975.

Further information is available on request.

'Flagyl' is a trade mark.
May & Baker Ltd., Dagenham,
Essex RM10 7XS.



TRADE MARK
INJECTION
**the complete
anaerobicide**

M&B May & Baker

A member of the Rhône-Poulenc
Group of Companies 

MA6579

“Marvellous”



Case history on file with Winthrop.

History:

vague chest pains and belching of a great deal of wind 'off and on for some time'.

X-ray:

barium meal showed a large irreducible hiatus hernia and gastric reflux. Stomach and duodenum appeared normal.

Treatment:

Pyrogastrone tabs 1 p.c./t.d.s. + 2 tabs nocte.

Results:

symptom-free within 3 weeks. To quote the patient's own words—“Marvellous”.

PYROGASTRONE

carbenoxolone/magnesium trisilicate/
dried aluminium hydroxide gel

positive healing power in
oesophagitis

Pyrogastrone (PL 0071/0138). For the treatment of oesophageal inflammation, erosions and ulcers due to hiatus hernia or other conditions causing gastric reflux and for the relief of heartburn, flatulence and other symptoms associated with reflux oesophagitis. Each tablet contains: carbenoxolone sodium B.P. 20mg, magnesium trisilicate B.P. 60mg, dried aluminium hydroxide gel B.P. 240mg, in a base containing sodium bicarbonate B.P. 210 mg and alginic acid B.P.C. 600 mg. Cartons of 100. **Adult Dosage.** One to be chewed immediately after meals, three times a day and two to be chewed at bedtime. **Basic N.H.S. Cost:** One day's treatment 56p (5 tablets). **Contraindications:** Severe cardiac, renal or hepatic failure. Patients on digitalis therapy unless serum electrolyte levels are monitored weekly to detect promptly the development of hypokalaemia. **Precautions:** Special care should be exercised with patients predisposed to sodium and water retention, potassium loss and hypertension (e.g. the elderly and those with cardiac, renal or hepatic disease) since the carbenoxolone content of Pyrogastrone can induce similar changes. Regular monitoring of weight and blood pressure which should indicate the development of such effects is advisable for all patients. A thiazide diuretic should be administered if oedema or hypertension occurs. (Spironolactone should not be used because it hinders the therapeutic action of carbenoxolone). Potassium loss should be corrected by the administration of oral supplements. No teratogenic effects have been reported with carbenoxolone sodium, but careful consideration should be given before prescribing Pyrogastrone for women who may become pregnant. Pyrogastrone is a registered trade mark. Made under licence from Biorex Laboratories Brit. Pat. No. 1390683. Further information available from:—

Winthrop Laboratories, Surbiton-upon-Thames, Surrey KT6 4PH.

WINTHROP

Immunology of nutritional Disorders

R K Chandra

No. 12 in the Current Topics in Immunology Series
An interpretative summary and critical analysis of all available data on nutritional regulation and adjustment of immune responses. It deals with the immunological changes in nutritional deficiency and excess. It is extensively referenced and contains original data.

Boards £9.95 120 pages 38 illus

Publication June

Intestinal Ischaemia

Adrian Marston

'Mr Marston is to be congratulated on an impeccably written well illustrated book which provides within a modest compass not only a thorough survey of contemporary knowledge of the subject with abundant references to the literature but also a clear account of the author's own personal practice in clinical management.'

British Journal of Hospital Medicine.

Boards £13 200 pages 75 illus

Current Surgical Practice: Volume 1

Edited on behalf of the Royal College of Surgeons of England by John Hadfield and Michael Hobsley

'This book will be essential reading for all fellowship candidates, and, in addition, all surgeons will find it of absorbing interest in keeping them fully informed of the growing edges of surgery. The publication of further volumes of these lectures will be eagerly awaited.' *British Journal of Surgery.*

Boards £16.50 Paper £6.95 280 pages 69 illus

Current Surgical Practice: Volume 2

Edited on behalf of the Royal College of Surgeons of England by John Hadfield and Michael Hobsley

... 'excellent evidence of the College's continuing interest in raising the standards of surgical education.' *British Journal of Surgery.*

Paper £11 390 pages 114 illus



Edward Arnold

41 Bedford Square, London WC1B 3DQ

Hypothalamic and Pituitary Hormones

The Proceedings of a Symposium organised by the Association of Clinical Pathologists

Edited by G. K. McGowan and G. Walters

CONTENTS

Editors' foreword ● Anatomy of the hypothalamus and pituitary gland ● Pituitary and hypothalamic physiology ● Relationships of structure with function of the gonadotrophins ● Purification of anterior pituitary and hypothalamic hormones ● Cytochemical methods of hormone assay ● Secretion of hypothalamic and pituitary hormones by non-endocrine tumours ● Secretion of pituitary-like peptides by the human placenta ● Disorders of prolactin secretion ● Disorders of gonadotrophin secretion ● Gonadotrophin-releasing hormone ● Thyrotrophin-releasing hormone in clinical practice ● Therapeutic use of human growth hormone ● Management of acromegaly ● The posterior pituitary and diabetes insipidus

PRICE: Inland £4.00; Abroad US\$10.00 including postage

Payment must be enclosed with order or a surcharge of 30p will be made for rendering invoices and statements

This publication can be ordered now from: The Publishing Manager

JOURNAL OF CLINICAL PATHOLOGY

B.M.A. House, Tavistock Square, London WC1H 9JR

STATISTICS AT SQUARE ONE


by T. D. V. SWINSCOW

from the British Medical Journal

The statistical testing of data is indispensable in many types of medical investigation and a help on countless occasions in clinical practice. This book provides step-by-step instruction. Subjects covered include standard deviation, χ^2 tests, t tests, non-parametric tests, and correlation. The book includes sections on Fisher's exact probability test and rank correlation not published in the *B.M.J.* series. Methods specially adapted to pocket calculators.

"The ability to put symbols in sequence may well be one of the greatest advances in man's development . . . This excellent and attractive volume will give you an idea into which category an article or projected article fits. The ink you save may be your own. It is superb value."
O'Donnell, Barry, *British Medical Journal*, 1977, 1, 451.

"... this gem of a practical booklet squeezes the essence of biostatistics into 75 well-written, well-organized pages. Newcomers to the field will like the way obscure concepts are clarified; experts will find the book valuable as a teaching aid."
de Jong, Rudolph, H., *J.A.M.A.*, 1977, 237, 1874.



Fifth edition

Now available

PRICE: Inland £2.00

Overseas US\$5.00

Payment must be enclosed with order or a surcharge of 50p will be made for rendering invoices and statements

ORDER YOUR COPY NOW

*From: The Publisher,
British Medical Journal,
BMA House,
Tavistock Square,
London WC1H 9JR*

or through any leading bookseller